Comparison of anti-bacterial prophylactic properties of two different vascular grafts: action of anti-bacterial graft coating and systemic antibiotic treatment.
The main problem associated with artificial vascular devices is the risk of bacterial infections, mostly sustained by coagulase negative Staphylococci or Staphylococcus aureus. Many efforts have been made to identify materials refractory to bacterial adhesion. The aim of our study is to verify the antimicrobial properties of two kinds of vascular prosthesis to prevent early onset infections and the efficacy of the concomitant action of a systemic antibiotic treatment. Adult male Wistar rats were used. We subcutaneously implanted in four groups a silver-coated prosthesis fragment, and a rifampicin-soaked prosthesis fragment in the remaining four groups. We inoculated in the site of implant a high bacterial burden of S. aureus in four groups and a low burden in the remaining groups. Systemic levofloxacin was administered for seven days in four groups representing the two kinds of prosthesis; after 21 days the rats were sacrificed, prosthesis fragments were sonicated and the corresponding supernatants were plated for bacterial counts. The rifampicin-soaked prostheses explanted from rats treated with levofloxacin were sterile, regardless of the bacterial inoculum. In other groups some prostheses were colonized. In the experimental rat model used, the action of local and systemic antibiotic treatment was able to reduce colonisation of artificial prostheses.
Artini
M
M
Department of Public Health Sciences, Sapienza University, Rome, Italy.
Scoarughi
G L
GL
Papa
R
R
Cellini
A
A
Avanzolini
C
C
Mileto
E
E
Rizzo
L
L
Selan
L
L
D000818:Animals; D019072:Antibiotic Prophylaxis; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000627:therapeutic use*; D016459:Prosthesis-Related Infections / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000494:pharmacology*; D012834:Silver / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy
D012834:Silver; D064704:Levofloxacin; D015242:Ofloxacin; D012293:Rifampin